The vision: Knowledge-based economically feasible biotechnological processes

Based on bundled innovations made by about 150 researchers the Austrian Center of Industrial Biotechnology plans to make the development of bioprocesses more transparent, predictable and thus faster, calculable and cheaper.

In contrast to todays research strategies which mostly rely on empiricism and trial and error, interdisciplinary research of ACIB will provide insight in biological production tools and systems on a molecular level, and link this knowledge to the development and management of bioprocesses. Thus ACIB will enable novel, predictable and economically feasible
production processes in a bio-based industry.

This is the type of interdisciplinary research ACIB will dedicate itself to.

Record of success

As well A-B as ACBT can look back at very successful work during the past years. The scientific orientation of the research work lead to about 500 scientific publications, the application-oriented one to about 20 patents and patent applications, respectively. ACBT succeeded in the development of new technologies for a more efficient production of recombinant pharma-proteins with bacterial and mammalian cell expression systems. Five processes for industrial biocatalytic production developed by A-B were already implemented by our industrial partners up to multi-ton scale.

Outstanding examples for the developments of both centres are for instance the autoprotease-fusion protein-technology for the expression of new and high-quality biopharmaceutical agents in E.coli and the enantiomerically pure intermediates for ACE-inhibitors and an antiplatelet drug which ranks among the top-ten of pharmaceuticals. Furthermore, the successful work was honoured with a series of scientific awards such as the well renowned Dr. Wolfgang Houska Award of the B&C Private Foundation remunerated with €100.000.